Koru Medical Systems, Inc. · NASDAQ:KRMD
Koru Medical Systems — Q1 2026 Earnings Presentation
14 slides from Koru Medical Systems's earnings presentation, May 6, 2026
Slide 1: KORU Medical Systems Q1 2026 Earnings Call
KORU Medical Systems Q1 2026 Earnings Call May 6, 2026 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements dis
Slide 3: Q1 2026 Results and Recent Highlights
Q1 2026 Results and Recent Highlights Consistent Execution and Key Strategic Progress 1 Q1 revenue of $11.8M represents growth of 22% over the prior year period 2 Domestic core growth of ~12% continues to outpace core SCIg market International Core growth of ~35% represents continued momentum in via
Slide 4: Strategic Vision Intact; Progress Across Growth Pillars
Q1 2026 Results Strategic Vision Intact; Progress Across Growth Pillars KORU’S Strategic Growth Pillars Protect and Grow our Enable More Drugs, 1 2 Expand Internationally 3 Core Domestic Business Reach More Patients • SCIg recurring revenue base • Vial to PFS conversion; key • 8 non-Ig drugs in pipe
Slide 5: Pipeline Opportunities in SCIg and New Drug Therapies
Enabling New Drugs Pipeline Opportunities in SCIg and New Drug Therapies 8 in Pipeline 9 on Label Active Opportunities for New Drugs and Indications1 Drugs on KORU’s Freedom Infusion System’s Label Annual Global Commercial Drug Asset Infusions Estimate3 SCIg 5.4M3 Annual Infusions Estimated Deferoxa
Slide 6: Q1 Y/Y Revenue by Business
Q1 Financials Q1 Y/Y Revenue by Business Net Revenues; In Millions Domestic Core • Increased 12% y/y • Higher consumables from new patient starts $11.8 • Increased market share gains in new and existing $0.7 accounts 22% $9.6 International Core $0.3 $3.3 • Increased 35% y/y $2.4 • High pump and cons
Slide 7: Maintaining Guidance Despite Continued Tariff Headwinds
Q1 Financials Maintaining Guidance Despite Continued Tariff Headwinds Consistent Performance >60% Gross Margin • 130 basis point reduction y/y 62.8% 62.3% 61 - 63% 62.4% • Higher production costs based on timing of production 61.5% runs at the end of 2025 amortized in Q1 • 87 basis point impact from
Slide 8: Cash Usage of ($0.1M); Positive CF from Operations
Q1 Financials Cash Usage of ($0.1M); Positive CF from Operations Cash Balance as of March 31, 2026: $8.8M Key Drivers • 1Q26 cash usage of $0.1M $8.9M +$0.9M $8.8M • Positive cash flow from ($0.1M) ($0.1M) operations ($0.8M) • 22% revenue growth and continued operating leverage • Q1 results aligned
Slide 9: 1Q 2026 Financial Highlights: Continued Demonstration of Operating Leverage
Q1 Financials 1Q 2026 Financial Highlights: Continued Demonstration of Operating Leverage and Disciplined Financial Profile 1Q 2026 1Q 2025 Y/Y Δ Revenue $11.8M $9.6M 22% Growth Gross Margin 61.5%1 62.8% 130bps Decrease OpEx $8.1M $7.3M 11% Increase Net Loss ($0.8M) ($1.2M) 31% Improvement Adj. EBIT
Slide 10: Reiterating 2026 Guidance
Outlook Reiterating 2026 Guidance Revenue Gross Margin Profitability Growth Profile Metrics $47.5-$50M, Positive cash flow 61-63% 15-22% growth & positive Adj. EBITDA Key Drivers/Milestones Key Drivers/Milestones Key Drivers/Milestones • Continued U.S. and • Pricing and manufacturing • Operating lev
Slide 11: Execution Milestones on Path to Accelerated Revenue Growth
Outlook Execution Milestones on Path to Accelerated Revenue Growth Reiterating 2026 Financial Guidance • 15-22% revenue growth • Positive Adjusted EBITDA and positive cash flow Enable More Drugs, Reach More Patients • Add 4 new pipeline collaborations for FY26: 2 of 4 complete • Deferoxamine 510(k)
Slide 12: Strategically Positioned for Accelerated Long Term Growth
Outlook Strategically Positioned for Accelerated Long Term Growth Financial Goals3 Recent Accomplishments1 $100M revenue Strong Fundamentals, Significant Opportunity1 22% 1Q26 revenue growth over prior year Accelerated Large and growing market period double-digit for SC drug delivery; ~95 >10mL drug
Slide 13: Appendix
Appendix 13
Slide 14: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by othe